Skip to main content
. 2006 Jun 23;103(27):10391–10396. doi: 10.1073/pnas.0600937103

Fig. 3.

Fig. 3.

Association of combined tumor B7-H1 and B7-H4 expression with cancer-specific survival for 259 patients with clear cell RCC. The cancer-specific survival rates at 1, 2, and 3 years after nephrectomy were 85.9% (3.6%, 77), 70.9% (5.0%, 52), and 60.9% (5.8%, 27), respectively, for patients with B7-H1-positive and B7-H4-positive tumors compared with 98.3% (1.7%, 54), 94.0% (3.4%, 32), and 94.0% (3.4%, 19), respectively, for patients with B7-H1 and B7-H4 negative tumors and 94.1% (2.3%, 95), 89.5% (3.2%, 64), and 89.5% (3.2%, 42), respectively, for patients with singly positive tumors.